A prior study of a larger cohort of ovarian cancer patients found ABCB1 fusions in 8% of patients and BRCA1/2 reversions in another 5%, suggesting that resistance mechanisms are heterogeneous and likely to be found at low frequencies97. The gene discussed is BRCA1; the disease is ovarian carcinoma.